What happens to the CMC joint in thumb basal arthritis

The trapeziometacarpal (CMC) joint connects the base of the thumb to the trapezium bone in the wrist. Its distinctive saddle shape gives the thumb its exceptional range — opposition, rotation, fine grip — but that same geometry concentrates compressive force onto a relatively small cartilage surface every time the hand pinches or grips. Across a lifetime of daily use, this mechanical reality makes the thumb base one of the most commonly affected sites in osteoarthritis globally.

Cartilage loss here follows a recognised progression, classified by the Eaton-Littler system. Early stages (I–II) bring mild joint-space narrowing and ligamentous laxity; advanced stages (III–IV) involve subchondral change, osteophyte formation, and gradual collapse of joint architecture. Pain on gripping and pinching is the hallmark, and it tends to arrive well before the joint reaches end-stage on imaging. Measurable loss of grip and pinch strength typically follows as the hand learns to guard the painful joint. Thenar muscle wasting and a squared or shelf-like contour at the thumb base can develop in more established disease.

Functionally, the impact extends well beyond pain: opening a jar, turning a key, or holding a pen can become unreliable. Yet the traditional clinical pathway has offered limited middle ground — symptom management through analgesia, splinting, and palliative injection on one side, and irreversible surgery on the other.

Why an outpatient injection changes what is possible

Trapeziectomy — surgical removal of the trapezium bone, often combined with ligament reconstruction (LRTI) — has long been the standard operative answer for thumb basal arthritis that fails conservative care. It reliably reduces pain, but the trade-off is substantial: recovery typically extends over several months, full return of grip strength is not guaranteed, and the procedure is irreversible. Once the trapezium is removed, it cannot be restored, and that forecloses a category of future options by default.

For surgeons, the joint's small, constrained anatomy adds further demands: accurate debridement, mechanical containment of any implanted material, and arthroscopic access all require theatre time, general or regional anaesthesia, post-operative immobilisation, and a controlled, dry operative field.

That same constrained anatomy, however, is an asset for an injectable scaffold. A small joint volume means an injected collagen material concentrates within the space rather than dispersing, and image-guided placement — ultrasound or fluoroscopy — allows accurate delivery without an incision. The procedure is carried out in an outpatient clinic under local anaesthesia; no operative field is needed, and nothing is removed from the joint. The structural architecture of the thumb remains intact, which means surgical pathways, should they ever become necessary, are not compromised by having chosen this route first.

How the ChondroFiller injection works in the joint

The delivery mechanism distinguishes ChondroFiller injection from other intra-articular treatments in a clinically meaningful way. The product is a CE-marked Class III medical device — an acellular solution of murine-derived Type I collagen that arrives at the joint as a liquid and transitions to a stable gel within minutes of injection, conforming to the contours of the joint space.

Once in place, the scaffold becomes chemotactic: it signals to progenitor cells in the surrounding synovium and subchondral bone, drawing them into the matrix. Those recruited cells mature into chondrocytes — the specialised cells that produce and maintain cartilage tissue — and begin progressively replacing the collagen scaffold with biological repair material. This sequence of scaffold placement, cell migration, chondrogenic differentiation, and tissue formation is what matrix-induced chondrogenesis describes. No external cells are introduced at any stage; the repair is driven entirely by the patient's own biology.

The process unfolds over weeks to months as the scaffold is gradually resorbed. Crucially, gelation occurs in the joint's natural fluid environment, which means the procedure does not depend on the dry operative field that arthroscopic techniques require.

At the London Cartilage Clinic on Harley Street, ChondroFiller injection is delivered as an outpatient procedure under local anaesthesia. Ultrasound guidance is used to place the material accurately within the thumb CMC joint — a precise, image-controlled approach that requires no incision and no theatre booking.

What the clinical evidence shows

The principal clinical dataset comes from Corain et al. (2023), a prospective study of 43 patients with trapeziometacarpal osteoarthritis who received a single intra-articular ChondroFiller infiltration under fluoroscopic guidance. Patients were stratified by Eaton-Littler staging into Group A (Stage I–II, early-to-moderate disease) and Group B (Stage III–IV, advanced disease), enabling outcome comparisons across the full spectrum of thumb CMC arthritis.

At both 30 days and six months, both cohorts recorded statistically significant improvements across all primary measures: pain on the Numeric Rating Scale, upper-limb disability on the DASH questionnaire, grip strength by Jamar dynamometry, and pincer strength by pinch testing. The consistency across early-stage and advanced-stage groups is noteworthy — injection therapies more commonly show diminishing returns as structural deterioration progresses.

What separates these findings from the profile of a symptomatic injection — corticosteroid or hyaluronic acid, for instance — is the post-treatment MRI data. Follow-up imaging demonstrated reduced bone marrow oedema, diminished periarticular effusion, and measurable widening of the joint space: structural signals that neither corticosteroid nor viscosupplementation produce on imaging.

The study is a single-arm prospective series with a six-month follow-up horizon. It appears in manufacturer-adjacent documentation rather than as an independent peer-reviewed publication, and no randomised controlled trial comparing ChondroFiller injection to sham or to surgical trapeziectomy has yet been published for the thumb CMC joint. Longer-term durability data beyond 12 months in this specific joint remain limited. These are genuine evidence gaps — the positive functional and structural signals in the Corain dataset are meaningful, but they sit within a body of evidence that is still developing.

Which patients are suitable — and what advanced-stage treatment involves

Candidacy for ChondroFiller injection spans the full Eaton-Littler spectrum. The Corain et al. (2023) cohort enrolled patients from Stage I through Stage IV — Group A covering early-to-moderate disease and Group B covering advanced structural deterioration — and both groups showed meaningful gains in pain, function, and grip strength at six months. The treatment is not reserved for patients who present early.

That said, earlier intervention is generally advantageous. When subchondral damage is less advanced, more viable progenitor cells are available in the surrounding tissue to migrate into the scaffold and undergo chondrogenic differentiation. Patients at Eaton-Littler Stage I or II may therefore experience a more robust biological response, though the evidence does not exclude advanced-stage patients from benefit.

Advanced-stage disease: a dual-injection protocol

For patients with Kellgren-Lawrence Grade III or IV deterioration, a combination approach has been described that pairs ChondroFiller injection with Arthrosamid. The two products serve different functions and should not be conflated. ChondroFiller injection — directed at the bone ends — provides the regenerative scaffold, recruiting the patient's own cells to promote endogenous repair over time. Arthrosamid is a non-regenerative polyacrylamide hydrogel injected to cushion and support the synovium; it does not repair cartilage and is not used in a regenerative capacity here. In this protocol, each product is targeting a different structure within the same joint.

For patients who wish to monitor and sustain the joint long term, a structured programme incorporating periodic MRI review and bi-annual top-up ChondroFiller injections offers a way to track structural change and intervene before symptoms escalate again. Guide costs for the combination protocol and any longer-term monitoring programme should be confirmed with the London Cartilage Clinic on Harley Street.

The procedure, recovery, and how to book an assessment

The appointment itself is brief. ChondroFiller injection at the CMC joint is performed as an outpatient procedure under local anaesthesia — no theatre booking, no general anaesthetic, and no overnight stay. Ultrasound guidance confirms precise needle placement within the small joint space before the collagen solution is administered. Patients typically leave the clinic the same morning.

Recovery is substantially lighter than after trapeziectomy, which involves incision, bone removal, and a structured hand-therapy programme before grip and pinch strength can be safely loaded. Following ChondroFiller injection, there is no wound to heal and no reconstructed tissue to protect. Specific recovery timelines depend on individual anatomy and disease stage and should be discussed at a clinical assessment rather than assumed in advance.

For patients with thumb basal arthritis who want to understand whether this pathway is appropriate for their stage of disease — and whether the anatomy of their CMC joint makes them a suitable candidate — the clinical team at the London Cartilage Clinic on Harley Street carries out these assessments directly. Liquid Cartilage™ is delivered in the UK through LCC, the certified UK delivery centre for ChondroFiller injection. Appointments can be arranged at londoncartilage.com.

1. [1] Osteoarthritis at the base of the thumb. https://en.wikipedia.org/?curid=40934678 https://en.wikipedia.org/?curid=40934678
2. [2] Osteoarthritis. https://en.wikipedia.org/?curid=504841 https://en.wikipedia.org/?curid=504841